Skip to main content

Table 1 Patients' main characteristics

From: Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial

  All Patients who
underwent surgery
Patients who
were operated
Characteristics N % N % N %
  25   9   16  
Age       
Median
(range)
65.5
(39.8-80.5)
  60.0
(39.8-80.5)
  69.7
(40.7-81.9)
 
Gender       
   Male 16 64% 6 67% 10 63%
   Female 9 36% 3 33% 6 38%
Tumor location       0%
   Stomach 4 16% 1 11% 3 19%
   Small intestine 7 28% 4 44% 3 19%
   Peritoneum 7 28% 1 11% 6 38%
   Oesophagus 2 8% 0 0% 2 13%
   Rectum 4 16% 3 33% 1 6%
   Pelvis 1 4% 0 0% 1 6%
Tumor size (mm)       
   Median (range) 150 (36-280) 150 (45-280) 149 (36-200)
   ≤ 50 2 8% 1 11% 1 6%
   50 < - ≤ 100 7 28% 3 33% 4 25%
   > 100 16 64% 5 56% 11 69%
WHO PS       0%
   0 10 40% 4 44% 6 38%
   1 10 40% 5 56% 5 31%
   2 2 8% 0 0% 2 13%
   3 1 4% 0 0% 1 6%
   Not reported 2 8% 0 0% 2 13%
Best response to IM       
   PR 15 60% 6 67% 9 56%
   SD 7 28% 2 22% 5 31%
   PD 3 12% 1 11% 2 13%